Thymalin

Thymalin is the odd one out in the Khavinson catalogue. Where its siblings are defined molecules of two to four amino acids, its own literature calls it "a polypeptide complex isolated from the thymus" ( Khavinson et al., Bull Exp Biol Med 2020;170(1):118-22), obtained from calf thymus by mild acid extraction ( Morozov & Khavinson, Int J Immunopharmacol 1997). It is an animal-tissue extract with no sequence to quote, and its composition depends on the batch and the method.

The proposal is thymic and immune. In cultures of human haematopoietic stem cells, Thymalin reduced the stem marker CD44 and the intermediate marker CD117 by two- to threefold while raising the mature T lymphocyte marker CD28 by 6.8-fold — read by the authors as accelerated differentiation into CD28-positive T cells. Because the preparation is a mixture, no molecule has been identified as responsible.

Its originators report using it, with the dipeptide Thymogen, in people with chronic pathology and immune dysfunction; it has no approved indication in the United States or European Union. The most visible recent example is a 2021 report proposing it as an addition to COVID-19 care, with faster falls in IL-6, C-reactive protein and D-dimer ( Khavinson, Kuznik et al., Stem Cell Rev Rep 2021). Nobody outside the authors' network reproduced it, and it entered no national guideline.

The hazard profile is that of a biological extract, not a small synthetic peptide. Injected animal-derived protein carries a real if uncommon hypersensitivity risk, and regulators would expect documented control of transmissible agents in bovine-sourced material — something a buyer cannot verify. Stimulating T-cell activity is also not neutral in autoimmune disease or under immunosuppressive therapy.

Half-life, clearance and bioavailability cannot be defined for a mixture whose active constituent is unidentified.

A lyophilised powder for injection. Its real comparators are other thymic agents. Thymosin alpha-1 is a defined synthetic peptide reported as approved in over 35 countries for hepatitis B and C ( Goldstein & Goldstein, Expert Opin Biol Ther 2009), Thymogen is the dipeptide Glu-Trp, isolated from this very extract and then made synthetically — an unusually clear case of a field moving from mixture to molecule.

Thymalin's file dwarfs the rest of this family: PubMed returns on the order of 290 records, against roughly 140 for Epitalon and two for Testagen. The volume comes from decades of Soviet-era clinical reporting, and that is where the honest reading gets uncomfortable — largely small, unblinded, single-centre series published before modern reporting standards, most in Russian, many without retrievable full text. Quantity of publication and quality of evidence are independent variables.

For deeper dives on this peptide, see:

• Thymalin benefits and areas of interest
• Thymalin side effects and safety context
• Thymalin dosing concepts (educational)
• Thymalin research and evidence overview

Is Thymalin a peptide bioregulator like Epitalon? It is sold alongside them but is a different kind of substance: Epitalon is one defined four-amino-acid molecule, Thymalin an extract containing many polypeptides from calf thymus.

Was there really a COVID-19 study? Yes — a 2021 peer-reviewed report of faster resolution of inflammatory markers alongside standard therapy, from the group that developed the preparation, never independently replicated.

How does it compare with thymosin alpha-1? Thymosin alpha-1 is a chemically defined synthetic peptide with marketing approval in dozens of countries for viral hepatitis and a far better trial record. Thymalin is an undefined mixture.

Is it approved in the United States or Europe? No. It holds neither FDA nor EMA authorisation and is not an approved biologic in either territory.